The efficacy and safety of Metoprolol as add-on treatment to standard of care in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy aged 8-16 years. A randomized, double-blind, placebo-controlled study

The efficacy and safety of Metoprolol in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy

What is metoprolol? Could it help in developing new method of treatment for patients suffering from cardiomiopathy associated with the Duchenne Muscular Dystrophy (DMD), a rare and serious genetic disorder characterised by progressive muscle degeneration and weakness?

Learn of the project conducted by Magdalena Bazgier M.D. and her team of fellow researchers led by Joanna Kwiatkowska, Ph.D., D.Sc. and see why it might bring an important breakthrough in the fight against the disease.

Would you like to conduct world-changing research just like Magdalena Bazgier, M.D.? See our educational offer for future students and doctoral researchers. You can also apply for a position at the Medical University of Gdańsk and pursue your scientific journey.

Magdalena Bazgier, M.D.

Doctoral researcher at the Department of Paediatric Cardiology and Congenital Heart Defects, Medical University of Gdańsk

Ph.D. student and a doctor of medicine (graduated 2020) conducting her research in the field of, among others, paediatric cardiology. Awarded at the 15th Warsaw International Medical Congress (2019) and Juvenes Pro Medicina (2020) as the co-author of prestigious publications.